Openbookopenbook
Equity
Argen-X(0QW0)
EUR --+0.00%
Reward68High
Risk39Moderate
📊75%Data
Strong 31% profit margin · Revenue growing 73% YoY
0QW0
+0.0 · +0.00%
EUR · LSE
Argen-X |
Growth Machine
Market Cap:13.37Bn
ℹ️
Reward Rating
68
High
Top 25% (model universe)
75% data coverage
ℹ️
Risk Rating
39
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 0QW0 to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Argen-X?

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.

0QW0 · Verdict

Solid reward · moderate risk

0QW0 stands out on growth and volatility, but watch the cash flow signal.

Based on 88% data coverage

0QW0 · Verdict

What’s working & what to watch

Strengths 3

  • Growth93/100

    Revenue +63.5% CAGR

  • Volatility75/100

    Above average

  • Balance sheet69/100

    Current ratio 7.29

Watchouts 1

  • Cash flow35/100

    -4% free-cash-flow margin

Model-based scoring. For information only — not financial advice.

What is Argen-X?

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is listed on the LSE in UK, with a market capitalisation of 13.37B.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: High (68)

The scoring profile indicates moderate reward potential, with growth and valuation as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market Cap13.37B
P/E RatioN/A
Dividend YieldN/A
52 Week High809.8
52 Week Low456.8
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares Outstanding32M
No. of Employees1,863
IndustryN/A
ExchangeLSE
Beta-0.087
CurrencyEUR
Websiteargenx.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.